Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$55.45 USD

55.45
10,808,187

+1.13 (2.08%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?

AVEO Pharmaceuticals, Inc. (AVEO) is expected to report fourth-quarter 2016 results this month.

    What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?

    Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.

      Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?

      Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.

        Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4

        Nektar Therapeutics (NKTR) reported loss of 28 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of loss of 26 cents.

          Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4

          Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.

            Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?

            Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.

              Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y

              Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.

                Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?

                Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Arpita Dutt headshot

                  Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs

                  Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.

                    Joseph Lu headshot

                    Bristol Myers' Future Unsure as Carl Icahn Takes Stake

                    Could Bristol-Myers Squibb Company (BMY) soon be put on the market for sale as activist investor, Carl Icahn, takes interest in the company?

                      Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

                      Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

                        Joseph Lu headshot

                        Can Carl Icahn Save Bristol Myers Squibb?

                        Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.

                          Arpita Dutt headshot

                          Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ

                          The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.

                            Arpita Dutt headshot

                            Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi

                            Key highlights this week include earnings results from Allergan (AGN) and Glaxo, Sanofi's update regarding Praluent and Teva's ongoing woes.

                              Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints

                              Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.

                                Sweta Killa headshot

                                Q4 Earnings Faring Well for Pharma ETFs

                                Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.

                                  Portola, HealthCare Royalty Partners Ink $150 Million Deal

                                  Portola (PTLA) announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR) for $150 million.

                                    Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC

                                    Bristol-Myers Squibb Company (BMY) announced that the FDA has approved an injectable form of immuno-oncology drug Opdivo

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling

                                      Key highlights this week include a court ruling in the Copaxone patent infringement lawsuit and earnings results from companies like Pfizer (PFE).

                                        Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales

                                        Roche beat on earnings but missed on sales in 2016 due to decline in sales of Lucentis, Pegasys, Avastin and Tarceva.

                                          Implied Volatility Surging for Bristol-Myers Squibb Co. (BMY) Stock Options

                                          Bristol-Myers Squibb Co. (BMY) warrants investors' attention based on moves in the options market lately.

                                            Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE

                                            Two pharma giants - Pfizer and Lilly - are set to report fourth-quarter results on Jan 31. Let's see how things are shaping up for this quarter.

                                              Arpita Dutt headshot

                                              Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint

                                              Key highlights this week include earnings reports from companies like Bristol-Myers (BMY) as well as the J&J-Actelion deal.

                                                Bristol-Myers (BMY) Misses on Q4 Earnings, Beats on Sales

                                                Bristol-Myers (BMY) reported fourth quarter earnings of 63 cents on revenues of $5.23 billion.

                                                  Bristol-Myers (BMY) Q4 Earnings Miss Estimates

                                                  Bristol-Myers (BMY) reported fourth quarter earnings of 63 cents on revenues of $5.23 billion.